Trichostatin C
Trichostatin C is an inhibitor for histone deacetylase (HDAC), induces apoptosis and arrests cell cycle at G2/M phase, and exhibits anticancer activity against lung cancer and urothelial bladder cancer. Trichostatin C induces differentation of Friend leukemic cells. Trichostatin C exhibits antifungal activity.
For research use only. We do not sell to patients.
- CAS No.: 68676-88-0
- Formula: C23H32N2O8
- Molecular Weight:464.51
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
|
HDAC1 |
HDAC6 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A2058 | IC50 |
37.3 μM
Compound: 3
|
Cytotoxicity against human A2058 cells assessed as reduction in cell viability
Cytotoxicity against human A2058 cells assessed as reduction in cell viability
|
[PMID: 32005414] |
| A549 | IC50 |
25.01 μM
Compound: 3
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability
Cytotoxicity against human A549 cells assessed as reduction in cell viability
|
[PMID: 32005414] |
| HEK293 | IC50 |
>100 μM
Compound: 10
|
Cytotoxicity against human HEK293 cells after 96 hrs by MTT assay
Cytotoxicity against human HEK293 cells after 96 hrs by MTT assay
|
[PMID: 25556102] |
| HeLa | IC50 |
>200 μM
Compound: 10
|
Cytotoxicity against human HeLa cells after 96 hrs by MTT assay
Cytotoxicity against human HeLa cells after 96 hrs by MTT assay
|
[PMID: 25556102] |
| HepG2 | EC50 |
46.02 μM
Compound: 10
|
Up-regulation of transcriptional activity of human CLA-1 promoter region -1055 to -62bp transfected in HepG2 cells by luciferase reporter gene assay
Up-regulation of transcriptional activity of human CLA-1 promoter region -1055 to -62bp transfected in HepG2 cells by luciferase reporter gene assay
|
[PMID: 25556102] |
| HepG2 | IC50 |
>200 μM
Compound: 10
|
Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay
|
[PMID: 25556102] |
| HepG2 | IC50 |
17.82 μM
Compound: 3
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability
|
[PMID: 32005414] |
| L02 | IC50 |
>200 μM
Compound: 10
|
Cytotoxicity against human LO2 cells after 96 hrs by MTT assay
Cytotoxicity against human LO2 cells after 96 hrs by MTT assay
|
[PMID: 25556102] |
| MCF7 | IC50 |
18.87 μM
Compound: 3
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability
|
[PMID: 32005414] |
| MIA PaCa-2 | IC50 |
37.88 μM
Compound: 3
|
Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability
Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability
|
[PMID: 32005414] |
| SW480 | IC50 |
72 μM
Compound: 5
|
Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by EZ-Cytox colorimetric assay
Cytotoxicity against human SW480 cells assessed as reduction in cell viability incubated for 72 hrs by EZ-Cytox colorimetric assay
|
[PMID: 34455777] |
| U2OS | IC50 |
>200 μM
Compound: 10
|
Cytotoxicity against human U2OS cells after 96 hrs by MTT assay
Cytotoxicity against human U2OS cells after 96 hrs by MTT assay
|
[PMID: 25556102] |
| U2OS | IC50 |
94.9 μM
Compound: 5
|
Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs by EZ-Cytox colorimetric assay
Cytotoxicity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs by EZ-Cytox colorimetric assay
|
[PMID: 34455777] |
In Vitro
Trichostatin C (0-100 μM) exhibits inhibitory activity against HDAC1 and HDAC6, inhibits proliferations of cancer cells A549, J82 and SK-BR-3, with IC50s of 6.24, 4.16 and 0.6 μM, respectively[1].
Trichostatin C (0-10 μM) induces apoptosis in cells J82 through activation of caspase 3 and caspase 7[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A549, J82 and SK-BR-3
-
Concentration:0-100 μM
-
Incubation Time:72 h
-
Result:Inhibits proliferations of A549, J82 and SK-BR-3.
-
Cell Line:J82
-
Concentration:20-80 μM
-
Incubation Time:24 h
-
Result:Induced acetylation of α-Tubulin and Histone 3 (markers of HDAC1 and HDAC6 inhibition).
-
Cell Line:J-82
-
Concentration:0.1-10 μM
-
Incubation Time:48 h
-
Result:Activated 23.1, 61.7 and 62.3% caspase 3/7 at 0.1 μM, 1 μM and 10 μM.
Chemical Information
-
CAS No. 68676-88-0
-
Molecular Weight 464.51
-
Formula C23H32N2O8
-
SMILES
O=C(NO[C@H]1[C@@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)O)/C=C/C(C)=C/[C@@H](C)C(C2=CC=C(N(C)C)C=C2)=O
-
Structure Classification
-
Initial Source
Streptomyces sp. RK98-A74
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)